Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02YOO
|
||||
| Former ID |
DNC008662
|
||||
| Drug Name |
NISOXETINE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [467877] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H21NO2
|
||||
| InChI |
InChI=1S/C17H21NO2/c1-18-13-12-15(14-8-4-3-5-9-14)20-17-11-7-6-10-16(17)19-2/h3-11,15,18H,12-13H2,1-2H3
|
||||
| InChIKey |
ITJNARMNRKSWTA-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 57226-61-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
143845, 3249458, 5054385, 7980130, 8152773, 11466938, 11468058, 11486695, 14799314, 26752034, 29223594, 47206897, 47217006, 47365427, 47365428, 47515548, 47515549, 48035363, 48110689, 49699321, 49846232, 50064869, 50104694, 50647659, 57322302, 85753306, 85787336, 90341689, 92308889, 99381446, 103123188, 103224657, 104171195, 104306586, 117535777, 124750083, 124880820, 124880821, 126407913, 128217697, 134345867, 135003536, 135143164, 137016425, 142365343, 144203754, 162875691, 163425846, 170466483, 176483984
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent noradrenaline transporter | Target Info | Inhibitor | [529670] | |
| Sodium-dependent dopamine transporter | Target Info | Inhibitor | [529530] | ||
| Sodium-dependent serotonin transporter | Target Info | Inhibitor | [529824] | ||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesisP00001:Adrenaline and noradrenaline biosynthesis | ||||
| Parkinson disease | |||||
| Dopamine receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway | |||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathway | |||||
| Pathway Interaction Database | Alpha-synuclein signaling | ||||
| WikiPathways | Monoamine Transport | ||||
| NRF2 pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport | |||||
| Dopaminergic Neurogenesis | |||||
| Parkinsons Disease Pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport | |||||
| SIDS Susceptibility Pathways | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
| Ref 529530 | Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. Epub 2008 May 20.Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). | ||||
| Ref 529670 | Bioorg Med Chem Lett. 2008 Sep 15;18(18):4929-31. Epub 2008 Aug 22.Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. | ||||
| Ref 529824 | Bioorg Med Chem Lett. 2009 Jan 1;19(1):58-61. Epub 2008 Nov 13.1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.